Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ALGS

Aligos Therapeutics Inc

Apr 24 • 04:00PM ET

0.8290

Dollar change +0.0054
Percentage change 0.66	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.69	Insider Own	33.69%	Shs Outstand	72.00M	Perf Week	5.34%
Market Cap	62.73M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	45.18%	Shs Float	50.18M	Perf Month	-11.69%
Income	-87.68M	PEG	-	EPS next Q	-0.19	Inst Own	51.21%	Short Float	1.31%	Perf Quarter	20.14%
Sales	15.53M	P/S	4.04	EPS this Y	38.60%	Inst Trans	-4.24%	Short Ratio	1.65	Perf Half Y	38.99%
Book/sh	1.23	P/B	0.68	EPS next Y	1.80%	ROA	-57.73%	Short Interest	0.66M	Perf Year	-17.51%
Cash/sh	1.79	P/C	0.46	EPS next 5Y	-	ROE	-89.48%	52W Range	0.54 - 1.38	Perf YTD	24.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-87.70%	52W High	-39.93%	Beta	2.35
Dividend TTM	-	Quick Ratio	5.90	Sales past 5Y	46.14%	Gross Margin	80.24%	52W Low	53.86%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	5.90	EPS Y/Y TTM	-	Oper. Margin	-567.50%	RSI (14)	42.67	Volatility	10.01% 9.48%
Employees	66	Debt/Eq	0.12	Sales Y/Y TTM	11.66%	Profit Margin	-564.61%	Recom	2.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-	Payout	-	Rel Volume	1.66	Prev Close	0.82
Sales Surprise	25.56%	EPS Surprise	21.43%	Sales Q/Q	-24.20%	Earnings	Mar 12 AMC	Avg Volume	397.54K	Price	0.83
SMA20	-12.02%	SMA50	-7.34%	SMA200	3.84%	Trades		Volume	644,254	Change	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $3
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$2.50 → $3
Mar-23-22	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $4
Jan-07-22	Downgrade	JP Morgan	Overweight → Neutral	$30 → $12
Jan-06-22	Downgrade	Jefferies	Buy → Hold
Sep-09-21	Initiated	SVB Leerink	Outperform	$29
May-17-21	Resumed	Piper Sandler	Overweight	$47
Nov-10-20	Initiated	Piper Sandler	Overweight	$35
Nov-10-20	Initiated	JP Morgan	Overweight	$33
Nov-10-20	Initiated	Jefferies	Buy	$26
Nov-10-20	Initiated	Cantor Fitzgerald	Overweight	$28

Show Previous Ratings

Apr-09-24 08:00AM	Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects (GlobeNewswire)
Mar-27-24 09:55AM	Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
08:00AM	Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies (GlobeNewswire)
Mar-18-24 08:00AM	Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects (GlobeNewswire)
04:05PM	Loading…
Mar-12-24 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:05PM	Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Feb-26-24 08:00AM	Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire) +21.33%
Feb-20-24 08:00AM	Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 (GlobeNewswire)
Feb-13-24 08:00AM	Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments (GlobeNewswire) -6.18%
Jan-05-24 09:40AM	Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-07-23 04:05PM	Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) (GlobeNewswire)
Nov-24-23 10:26AM	13 Stocks Insiders are Buying Now (Insider Monkey) +5.29%
Nov-20-23 04:05PM	Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference (GlobeNewswire)
09:10AM	Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today? (InvestorPlace)
08:00AM	Loading…
Nov-13-23 08:00AM	Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile (GlobeNewswire) -14.13%
Nov-10-23 08:05AM	Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg) (GlobeNewswire) -9.26%
Nov-07-23 08:00AM	Aligos Therapeutics to Present Multiple Posters at AASLD's The Liver Meeting 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR- Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company's Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C) (GlobeNewswire)
Nov-03-23 04:30PM	Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data (GlobeNewswire)
Nov-02-23 06:57PM	Aligos Therapeutics Inc (ALGS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-30-23 01:06PM	Hedge Fund and Insider Trading News: Joseph Edelman, Ken Griffin, Seth Klarman, Two Sigma Advisors, Sculptor Capital Management, Aligos Therapeutics Inc (ALGS), The Progressive Corporation (PGR), and More (Insider Monkey)
Oct-26-23 04:05PM	Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023 (GlobeNewswire)
Oct-25-23 08:00AM	Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting 2023 (GlobeNewswire)
Oct-23-23 08:00AM	Aligos Therapeutics Announces $92 Million Private Placement Financing (GlobeNewswire) -21.52%
Oct-03-23 07:30AM	Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558 (GlobeNewswire)
Sep-21-23 07:30AM	Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009 (GlobeNewswire)
Aug-03-23 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-27-23 04:05PM	Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023 (GlobeNewswire)
Jul-19-23 07:30AM	Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009 (GlobeNewswire)
04:30PM	Loading…
Jun-21-23 04:30PM	Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Jun-07-23 07:30AM	Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Jun-05-23 06:09AM	We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-24-23 05:26PM	Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-12-23 05:05PM	Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos Oligonucleotide Platform for the Treatment of Liver Diseases (GlobeNewswire)
May-04-23 07:25PM	Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:05PM	Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 (GlobeNewswire)
Apr-17-23 06:51AM	Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 30% Dip In Price Shows Sentiment Is Matching Revenues (Simply Wall St.)
Apr-11-23 06:50PM	Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Mar-29-23 04:05PM	Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference (GlobeNewswire)
Mar-09-23 06:25PM	Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.21%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:05PM	Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023 (GlobeNewswire) -7.01%
Feb-16-23 08:00AM	Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (GlobeNewswire)
Feb-14-23 08:00AM	Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (GlobeNewswire) +7.24%
Feb-10-23 07:00AM	Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire) -11.11%
Feb-09-23 11:39AM	Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce (Benzinga) -8.06%
Feb-08-23 04:05PM	Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024 (GlobeNewswire)
Jan-23-23 07:53AM	Aligos Therapeutics (NASDAQ:ALGS) adds US$18m to market cap in the past 7 days, though investors from a year ago are still down 34% (Simply Wall St.) -6.31%
Jan-05-23 08:00AM	Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009 (GlobeNewswire) +5.32%
Dec-14-22 04:05PM	Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB) (GlobeNewswire)
Dec-08-22 08:00AM	Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting (GlobeNewswire)
Dec-05-22 05:13AM	We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Nov-04-22 08:05AM	Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLDs The Liver Meeting® 2022 (GlobeNewswire) -5.71%
08:00AM	Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLDs The Liver Meeting® 2022 (GlobeNewswire)
Nov-02-22 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-21-22 09:05AM	Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLDs The Liver Meeting® 2022 (GlobeNewswire)
Oct-19-22 04:15PM	Aligos Therapeutics to Announce Third Quarter Results November 2, 2022 (GlobeNewswire)
Oct-18-22 07:30AM	Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institutes 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA (GlobeNewswire)
Oct-14-22 08:00AM	Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755 (GlobeNewswire)
Sep-29-22 08:40AM	Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud (Benzinga)
Sep-28-22 04:32PM	Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud (GlobeNewswire)
Aug-16-22 08:00AM	The past year for Aligos Therapeutics (NASDAQ:ALGS) investors has not been profitable (Simply Wall St.) -5.13%
Aug-04-22 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-27-22 04:05PM	Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022 (GlobeNewswire)
Jul-25-22 08:00AM	Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184 (GlobeNewswire)
Jun-27-22 12:20PM	Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation (Simply Wall St.)
Jun-22-22 08:00AM	Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Livers Digital International Liver Congress 2022 (GlobeNewswire)
Jun-06-22 08:00AM	Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential (GlobeNewswire) +9.16%
May-23-22 04:05PM	Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference (GlobeNewswire) +8.33%
May-04-22 04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results (GlobeNewswire)
May-03-22 08:00AM	Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Livers International Liver Congress 2022 (GlobeNewswire)
Apr-27-22 04:05PM	Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022 (GlobeNewswire)
Apr-05-22 09:25AM	Alnylam's (ALNY) Vutrisiran NDA Faces Delay in FDA Decision (Zacks)
Apr-04-22 08:00AM	Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development (GlobeNewswire)
Mar-22-22 11:09AM	After patient hospitalized, Peninsula drug developer stops 2nd chronic hepatitis B program this year (American City Business Journals)
08:00AM	Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio (GlobeNewswire)
Mar-10-22 04:05PM	Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-02-22 04:05PM	Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022 (GlobeNewswire)
Feb-11-22 07:00AM	Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes (Investor's Business Daily)
Feb-03-22 04:05PM	Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-26-22 08:00AM	Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401) (GlobeNewswire)
Jan-18-22 04:21AM	We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully (Simply Wall St.) -7.06%
Jan-14-22 04:51PM	Biotech's virtual JPM conference was a big deal. But, actually, there wasn't one (American City Business Journals)
Jan-12-22 09:31AM	10 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang (Insider Monkey) -5.29%
Jan-11-22 09:12AM	Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH (GlobeNewswire) +6.43%
Jan-07-22 12:24PM	Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt (Zacks) -14.81%
Jan-06-22 06:21PM	Why Aligos Therapeutics Stock Crumbled Today (Motley Fool) -56.74%
05:53PM	Peninsula biotech sheds half its value, ditches hepatitis B program after clinical failure (American City Business Journals)
11:19AM	Aligos Therapeutics Halts Development of Hepatitis B Drug (Investing.com)
08:00AM	Aligos Halting Further Development of STOPS Drug Candidate, ALG-010133 (GlobeNewswire)
Dec-21-21 04:05PM	Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-21 08:00AM	Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study (GlobeNewswire) -9.18%
Dec-07-21 08:00AM	Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021 (GlobeNewswire)
Nov-23-21 07:00AM	Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases (PR Newswire)
Nov-22-21 08:00AM	Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-18-21 04:05PM	Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors (GlobeNewswire)
Nov-15-21 04:05PM	Aligos Therapeutics to Present Virtually at the Jefferies London Healthcare Conference 2021 (GlobeNewswire)
Nov-12-21 08:00AM	Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021 (GlobeNewswire)

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nuechterlein Carole	Director	Oct 25 '23	Buy	0.76	7,933,601	6,004,149	11,025,941	Oct 27 04:15 PM

Open in Screener

PASG

Passage Bio Inc

Apr 24 • 04:00PM ET

1.24

Dollar change +0.01
Percentage change 0.81	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.86	Insider Own	33.07%	Shs Outstand	54.94M	Perf Week	-2.36%
Market Cap	76.40M	Forward P/E	-	EPS next Y	-0.98	Insider Trans	-0.17%	Shs Float	41.24M	Perf Month	-8.15%
Income	-102.06M	PEG	-	EPS next Q	-0.36	Inst Own	25.84%	Short Float	4.25%	Perf Quarter	44.15%
Sales	0.00M	P/S	-	EPS this Y	36.02%	Inst Trans	-5.98%	Short Ratio	4.96	Perf Half Y	85.35%
Book/sh	2.03	P/B	0.61	EPS next Y	18.04%	ROA	-51.80%	Short Interest	1.75M	Perf Year	22.77%
Cash/sh	1.86	P/C	0.67	EPS next 5Y	-	ROE	-65.29%	52W Range	0.58 - 1.79	Perf YTD	22.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.23%	ROI	-76.05%	52W High	-30.73%	Beta	1.29
Dividend TTM	-	Quick Ratio	7.22	Sales past 5Y	0.00%	Gross Margin	-	52W Low	115.61%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	7.22	EPS Y/Y TTM	25.46%	Oper. Margin	0.00%	RSI (14)	46.44	Volatility	9.14% 8.92%
Employees	58	Debt/Eq	0.24	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	38.47%	Payout	-	Rel Volume	0.11	Prev Close	1.23
Sales Surprise	-	EPS Surprise	22.28%	Sales Q/Q	-	Earnings	Mar 04 BMO	Avg Volume	352.88K	Price	1.24
SMA20	-3.97%	SMA50	-9.02%	SMA200	32.72%	Trades		Volume	39,304	Change	0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral	$29 → $6
Jul-01-21	Initiated	Raymond James	Outperform	$29
Jun-15-21	Initiated	BTIG Research	Buy	$25
Mar-04-21	Upgrade	Goldman	Neutral → Buy	$28 → $30
Feb-04-21	Initiated	Guggenheim	Buy	$25
Jan-25-21	Initiated	Wedbush	Outperform	$26
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight	$25 → $35
Dec-11-20	Initiated	Citigroup	Neutral	$28
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral	$25
Jun-25-20	Downgrade	Goldman	Buy → Neutral	$28
Mar-25-20	Initiated	Chardan Capital Markets	Buy	$30
Mar-24-20	Initiated	JP Morgan	Overweight	$25
Mar-24-20	Initiated	Goldman	Buy	$27
Mar-24-20	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-22-24 07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-24 12:00PM	Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know (Zacks) -6.43%
Mar-06-24 01:52PM	PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023 (InvestorPlace)
Mar-05-24 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Mar-04-24 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
07:00AM	Loading…
Feb-27-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.12%
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace)
Jan-31-24 07:30AM	Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-25-23 10:14PM	7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight (InvestorPlace)
Dec-20-23 07:00AM	Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities (GlobeNewswire) +7.35%
Nov-17-23 04:30PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-13-23 07:00AM	Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Oct-30-23 07:00AM	Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire) +6.91%
Oct-20-23 04:30PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines Conference (GlobeNewswire)
10:04AM	Loading…
Aug-11-23 10:04AM	Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobs (American City Business Journals)
Aug-07-23 07:15AM	Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.11%
07:00AM	Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Aug-01-23 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 07:00AM	Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors (GlobeNewswire)
Jul-24-23 12:37PM	Passage Bio reduces staff by 26% in latest round of job cuts (American City Business Journals) -5.31%
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey)
Jun-05-23 07:00AM	Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-11-23 07:00AM	Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
May-04-23 07:00AM	Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award (GlobeNewswire) +5.91%
Apr-21-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-29-23 09:02AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-27-23 07:00AM	Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-08-23 07:14AM	Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript (Insider Monkey)
12:42AM	Loading…
Mar-07-23 12:42AM	Q4 2022 Passage Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-01-23 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Feb-28-23 07:00AM	Passage Bio to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023 (GlobeNewswire) +7.69%
Feb-24-23 07:00AM	Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire) -7.87%
Feb-20-23 05:59PM	'We've turned the page': CEO says Passage Bio is building momentum after turbulent 2022 (American City Business Journals)
Feb-15-23 07:00AM	Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire)
Jan-20-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-23 07:39AM	After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain (Simply Wall St.)
Dec-14-22 12:13PM	Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder (Benzinga) +9.65%
07:00AM	Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Nov-21-22 05:24AM	Estimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG) (Simply Wall St.)
Nov-10-22 07:00AM	Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.83%
Nov-08-22 07:00AM	Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Nov-03-22 07:30AM	Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-14-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-11-22 12:25PM	Here's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash Wisely (Simply Wall St.)
Oct-10-22 07:00AM	Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer (GlobeNewswire)
Sep-26-22 07:00AM	Passage Bio to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-19-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-11-22 07:00AM	Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations (GlobeNewswire)
Aug-05-22 07:00AM	Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-04-22 07:00AM	Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-28-22 07:30AM	Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire) -7.98%
Jul-21-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-12-22 08:19AM	What Kind Of Investors Own Most Of Passage Bio, Inc. (NASDAQ:PASG)? (Simply Wall St.)
Jul-06-22 07:00AM	Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors (GlobeNewswire)
Jun-09-22 07:30AM	Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
Jun-08-22 07:30AM	Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy (GlobeNewswire)
Jun-01-22 10:19AM	Passage Bio and CEO Bruce Goldsmith part ways (American City Business Journals)
07:30AM	Passage Bio Announces Leadership Transition (GlobeNewswire)
May-20-22 04:01PM	Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.38%
May-18-22 07:00AM	Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting (GlobeNewswire) -5.35%
May-16-22 07:00AM	Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -7.65%
May-09-22 07:00AM	Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire) -10.31%
May-04-22 10:55AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.) +13.78%
May-03-22 02:13PM	UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire)
May-02-22 04:01PM	Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire)
Apr-22-22 04:01PM	Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-29-22 07:00AM	Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease (GlobeNewswire) +5.30%
Mar-28-22 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-15-22 11:22AM	Passage Bio trims workforce by 13%, narrows R&D focus to extend cash runway (American City Business Journals)
11:12AM	Passage Bio To Cut Workforce, Prioritize R&D Programs To Reduce Operating Expenses (Benzinga)
07:00AM	Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway (GlobeNewswire)
Mar-10-22 07:00AM	Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition (GlobeNewswire)
Mar-03-22 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -11.59%
Mar-01-22 07:00AM	Passage Bio to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-24-22 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022 (GlobeNewswire)
Feb-11-22 11:00AM	Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium (GlobeNewswire) -9.29%
Feb-01-22 12:49PM	What Kind Of Investors Own Most Of Passage Bio, Inc. (NASDAQ:PASG)? (Simply Wall St.)
Jan-31-22 07:00AM	Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 11 (GlobeNewswire) +6.79%
Jan-10-22 07:00AM	Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline (GlobeNewswire)
Jan-03-22 07:00AM	Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-21 07:00AM	Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis (GlobeNewswire)
Dec-08-21 02:35PM	Passage Bio further expands gene therapy research partnership with Penn (American City Business Journals)
07:00AM	Passage Bio Announces Pipeline Expansion and Clinical Program Update (GlobeNewswire)
Nov-30-21 11:08AM	Moore Kuehn, PLLC Encourages Investors of Passage Bio, Inc. to Contact Law Firm (Newsfile)
Nov-19-21 04:00PM	Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-12-21 05:51AM	Top 10 Stock Picks of Jacob Dofts Highline Capital Management (Insider Monkey)
Nov-09-21 07:00AM	Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference (GlobeNewswire)
Nov-04-21 07:00AM	Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Nov-01-21 03:05PM	Companies Like Passage Bio (NASDAQ:PASG) Are In A Position To Invest In Growth (Simply Wall St.) +7.57%
Oct-28-21 07:00AM	Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021 (GlobeNewswire)
Sep-29-21 04:42PM	Time to Go Bottom Fishing? These 3 Strong Buy Stocks Are on Sale (TipRanks)
Sep-27-21 07:00AM	Passage Bio to Participate in Upcoming October Conferences (GlobeNewswire)
Sep-17-21 04:01PM	Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-21 07:00AM	Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors (GlobeNewswire)
Sep-02-21 07:00AM	Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference (GlobeNewswire)
Aug-05-21 07:00AM	Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights (GlobeNewswire) +5.77%

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Forman Mark S	CHIEF MEDICAL OFFICER	Feb 13 '24	Sale	0.97	1,638	1,589	48,631	Feb 13 07:34 PM
Borthwick Kathleen	SVP, INTERIM CFO	Feb 13 '24	Sale	0.97	1,470	1,426	28,466	Feb 13 07:36 PM
Forman Mark S	Chief Medical Officer	Jan 02 '24	Sale	0.91	15,813	14,390	45,269	Jan 03 04:21 PM
Cale Edgar B.	GC & Corporate Secretary	Jan 02 '24	Sale	0.91	15,813	14,390	45,995	Jan 03 04:19 PM
King Simona	Chief Financial Officer	Jul 28 '23	Option Exercise	0.00	31,250	0	35,447	Aug 01 04:36 PM
King Simona	Chief Financial Officer	Jul 28 '23	Sale	0.88	11,453	10,079	23,994	Aug 01 04:36 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 28 '23	Buy	0.84	575,195	483,164	8,034,000	Jun 29 04:42 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 27 '23	Buy	0.84	617,382	518,601	7,458,805	Jun 29 04:42 PM
Fotopoulos Alexandros	Chief Technical Officer	Jun 16 '23	Sale	0.93	4,052	3,778	28,693	Jun 20 04:10 PM
Fotopoulos Alexandros	Chief Technical Officer	Jun 15 '23	Option Exercise	0.00	12,500	0	32,745	Jun 20 04:10 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ALGS

Aligos Therapeutics Inc

PASG

Passage Bio Inc

Upgrade your FINVIZ experience